Alector Inc logo

Alector Inc

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. The company is developing AL001, an antibody that targets delta-like ligand 4-Notch to address abnormal signaling triggered by microglia in Alzheimer's disease prevention and slowing in patients with mild cognitive impairment and early-stage Alzheimer's disease; AL101, an anti-TREM2 antibody targeting microglia function that is in Phase IIa clinical trial for the treatment of frontotemporal dementia; AL003, an anti-LINGO monoclonal antibody targeting oligodendrocyte precursor cells for myelination; and AL002 and AL004 for preventing or slowing disease progression in Parkinson's disease. The company was founded in 2013 and is headquartered in South San Francisco, California.

Latest events on Quartr

Previous Events for Alector Inc




United States of America

About the company

Investor Relations page

Dig deeper into the fundamentals using Quartr - Investor relations

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
Android play link
App store link
Quartr app screenshot